Protocol Ledger

NCT06119581 · Phase III · RECRUITING

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT06119581 sponsored by Eli Lilly and Company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-21 Enrollment: 1,264 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06119581
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,264 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06119581
Protocol FieldVerified Registry Value
NCT IdentifierNCT06119581
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,264 participants (ESTIMATED)
Registered Start Date2023-12-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06119581
Hospital Research SiteLocationSite Profile
Banner MD Anderson Cancer CenterGilbert, AZOpen Hospital Dossier ->
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI